Moleculin Biotech (MBRX) Set to Announce Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is scheduled to be issuing its quarterly earnings data after the market closes on Friday, May 10th. Analysts expect the company to announce earnings of ($3.59) per share for the quarter.

Moleculin Biotech Stock Performance

Moleculin Biotech stock opened at $4.94 on Thursday. Moleculin Biotech has a one year low of $4.28 and a one year high of $15.75. The business has a fifty day moving average of $6.19 and a two-hundred day moving average of $7.86. The company has a market cap of $11.00 million, a P/E ratio of -0.36 and a beta of 1.85.

Wall Street Analyst Weigh In

MBRX has been the subject of a number of research analyst reports. Roth Mkm restated a “buy” rating and issued a $40.00 price target on shares of Moleculin Biotech in a research report on Friday, April 12th. StockNews.com started coverage on Moleculin Biotech in a research report on Tuesday. They set a “sell” rating for the company. Finally, Maxim Group decreased their price target on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.